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Prefrontal Cortex of Subjects with Schizophrenia
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2Department of Psychiatry, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, Massachusetts,
United States of America
Dysfunction of prefrontal cortex in schizophrenia includes changes in GABAergic mRNAs, including decreased expression of
GAD1, encoding the 67 kDa glutamate decarboxylase (GAD67) GABA synthesis enzyme. The underlying molecular mechanisms
remain unclear. Alterations in DNA methylation as an epigenetic regulator of gene expression are thought to play a role but
this hypothesis is difficult to test because no techniques are available to extract DNA from GAD1 expressing neurons efficiently
from human postmortem brain. Here, we present an alternative approach that is based on immunoprecipitation of
mononucleosomes with anti-methyl-histone antibodies differentiating between sites of potential gene expression as opposed
to repressive or silenced chromatin. Methylation patterns of CpG dinucleotides at the GAD1 proximal promoter and intron 2
were determined for each of the two chromatin fractions separately, using a case-control design for 14 schizophrenia subjects
affected by a decrease in prefrontal GAD1 mRNA levels. In controls, the methylation frequencies at CpG dinucleotides, while
overall higher in repressive as compared to open chromatin, did not exceed 5% at the proximal GAD1 promoter and 30%
within intron 2. Subjects with schizophrenia showed a significant, on average 8-fold deficit in repressive chromatin-associated
DNA methylation at the promoter. These results suggest that chromatin remodeling mechanisms are involved in dysregulated
GABAergic gene expression in schizophrenia.
Citation: Huang H-S, Akbarian S (2007) GAD1 mRNA Expression and DNA Methylation in Prefrontal Cortex of Subjects with Schizophrenia. PLoS
ONE 2(8): e809. doi:10.1371/journal.pone.0000809
INTRODUCTION
Cortical dysfunction in schizophrenia and related disease is
associated with changes in GABAergic circuitry [1], including
altered expression of the 67 kDa isoform of glutamic acid
decarboxylase (GAD67), one to two key enzymes for GABA
synthesis in cortical interneurons. To date, at least 12 studies using
tissues from 6 independent brain collections reported down-
regulated expression for GAD67 [2]. In addition, in elderly
schizophrenia subjects, up-regulation of GAD67 levels was
observed [3]. Two lines of evidence point to an important role
for GAD67 in the neurobiology of schizophrenia: First, dysregu-
lated GAD67 expression in the chandelier subtype of GABA
neurons is thought to result in disruption of synchronized cortical
activity and impairment of working memory functions in
schizophrenia subjects [4]. Second, allelic polymorphisms within
GAD1, the gene encoding GAD67, confer genetic risk for
childhood-onset schizophrenia and accelerated loss of frontal gray
matter [5,6].
Given the importance of GAD67 for the pathophysiology of
schizophrenia, it will be important to gain further insight into the
molecular mechanisms that underly the reported GAD1 mRNA
alterations in cerebral and cerebellar cortex of schizophrenia
subjects [7,8]. Here we study the potential role of CpG
dinucleotide methylation, which at sites of proximal gene
promoters often functions as negative regulator of transcription
[9]. Recently, studies on prefrontal cortex of schizophenia subjects
identified a number of genes, including REELIN [10], COMT [11]
and SOX10 [12] which are affected by altered DNA methylation in
conjunction with changes in mRNA levels. Furthermore, it has
been suggested that in psychosis the DNA maintenance methyl-
transferase enzyme, DNMT1, is overexpressed in cerebral cortex
[13]. Based on these findings, decreased GAD1 mRNA expression
in interneurons of schizophrenia subjects would be predicted to be
associated with increased DNA methylation. However, it is
difficult to test this hypothesis directly given that to date no
reproducible technology exists to selectively collect-in postmortem
brain tissue-genomic DNA from nuclei of GAD1 expressing
neurons. Here, we present an alternative approach that is based
on the finding that in neurons, GAD1 gene expression is associated
with the tri-methylation of histone H3-lysine 4 (H3K4me3)
a chromatin mark that defines open chromatin at sites of active
transcription [14,15]. Therefore, we separated open and repressive
chromatin from human prefrontal cortex with site-specific anti-
methyl-histone specific antibodies, followed by GAD1 DNA
methylation studies for each of the two chromatin fractions
separately.
RESULTS
To find out if H3K4me3 at the Gad1 locus defines open chromatin
and gene expression, and to examine potential effects of
antipsychotic drug (APD) treatment on chromatin remodeling,
we monitored open (H3K4me3) and repressive (H3K27me3;
(Hampsey and Reinberg 2003; Sims et al. 2003) chromatin-
associated histone methylation at the Gad1 locus in a neural
differentiation assay for precursor cells from rat embryonic
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forebrain (Fig. 1A, see also Methods). In this assay, neuronal
differentiation is induced by withdrawal of fibroblast growth factor
2 (Fgf2) and addition of sodium valproate (VA) to the cell culture
medium [16]. In comparison to undifferentiated precursor cells
(‘‘+FGF2’’ in Fig. 1A, B), neurons (‘‘-FGF2/+VA’’ in Fig. 1A, B)
showed, on average, a 168-fold fold increase in Gad1 mRNA levels
by qRT-PCR, and this associated with a 30-fold increase in
H3K4me3 levels at the proximal Gad1 promoter (Fig. 1B). These
changes were consistent in 3/3 experiments. In contrast to these
dramatic increases in Gad1 mRNA and H3K4me3, levels of
H3K27me3–the repressive mark–showed a two-fold decrease upon
neural differentiation (Fig. 1B). Furthermore, cultured neurons
treated with the antipsychotic, clozapine (‘‘-FGF2+VA+Clz’’ in
Fig. 1B), did not show consistent changes in Gad1 mRNA, or
Gad1-associated H3K4me3 and H3K27me3. From these experi-
ments, we draw two conclusions: First, the tagging of Gad1
nucleosomes with H3K4me3-a histone mark previously associated
with open chromatin and actual or potential gene expression in
non-neuronal tissues and cell lines ([6]–indeed reflects neuronal
gene expression activity at that locus. Second, levels of open
(H3K4me3) and repressive (H3K27me3) histone methylation at
the Gad1 locus are not affected by treatment with the antipsychotic
drug, clozapine.
Next, we separated open (H3K4me3) and repressive
(H3K27me3) chromatin from postmortem human prefrontal
cortex prepared by micrococcal nuclease-based digestion prior to
immunoprecipitation as previously described [17,18] . Then, we
monitored GAD1 mCpG methylation in subclones of PCR
products amplified from the immunoprecipitated DNA after
bisulfite conversion. Altogether 70 primer pairs within 8kb of
GAD1 proximal promoter and 59end sequences were tested; 67
primers pairs produced amplicons that lacked sequence specificity
(data not shown). This was not surprising given that bisulfite-
conversion reduces the genetic code to a 3 letter code in the
absence of methylation. The design of suitable PCR primers is
further limited by the chromatin preparation technique that
produces mononucleosomes with less than 148 bp of genomic
DNA. The remaining 3 primer pairs (Suppl. Table S1) covered
altogether 12 CpG’s positioned between 21120 to +3400 bp from
the GAD1 transcription start site (Fig. 2A). Methylation frequen-
cies in repressive chromatin immunoprecipiated with anti-
H3K27me3 antibody were higher at 10/12 CpG dinucleotides,
in comparison to open chromatin fractionated with anti-
H3K4me3 antibody (Binomial test, p,0.01) (Fig. 2A upper
panel). Two CpG’s located within 200–250 bp upstream of GAD1
transcription start site remained unmethylated both in open and
repressive chromatin, and DNA methylation levels were overall
much lower at the promoter in comparison to intron 2 (Fig. 2A
upper panel). Next, we monitored GAD1 CpG methylation levels
in subjects diagnosed with schizophrenia and their matched
controls. Levels of GAD1 DNA methylation in open chromatin
(H3K4me3) were strikingly similar between schizophrenia subjects
and controls, with extremely low levels at the promoter (,0.5%)
(Fig. 2A lower panel, and Fig. 2B) and a higher methylation
frequency (approximately 15%) within intron 2 (Fig. 2A lower
panel, and Fig. 2C). Unexpectedly, however, GAD1 DNA
methylation in repressive chromatin (H3K27me3) of schizophre-
nia subjects was significantly different from control subjects: CpG
factor 2)-containing medium and (d–j) neurons differentiated in
medium without FGF2 but with VA (sodium valproate); notice that
precursors (a) , but not neurons (d) are defined by nestin immunore-
activity, while both type of cells express robust H3K4me3 immunore-
activity (c,f); (g,i) representative examples of neuronal marker (g, NeuN
and i, GABA) immunoreactivity. All images taken at 20610 magnifica-
tion. (B) (top) levels of Gad1 mRNA (y-axis, log scale), expressed relative
to 18S rRNA and (middle and bottom) chip-to-input ratios (y-axis, log
scale) of site-specific histone methylation (H3K4me3 and H3K27me3) in
the nucleosomes positioned 2374 to 2273 bp of rat Gad1 promoter.
Data expressed as mean +/2 S.E.M., with N=3 for each of the three
different culture conditions. Notice robust increase of Gad1 mRNA and
H3K4me3 levels in differentiated cultures (2FGF2+VA), in comparison
to undifferentiated cells (+FGF2); that treatment with the antipsychotic
clozapine did not affect histone methylation and Gad1 gene expression
in cultured neurons. VA=Valproic acid, Clz = Clozapine.
doi:10.1371/journal.pone.0000809.g001
R
Figure 1. Histone methylation changes at the Gad1 promoter in
a neuronal differentiation assay. (A) (a–j) Digitized images showing (a–
c) undifferentiated neural precursors grown in FGF2 (fibroblast growth
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methylation frequencies were on average 3.5% in the control
cohort but only 0.4% in the disease cohort (Fig. 2A lower panel,
and Fig. 2B). This DNA methylation deficit in repressive GAD1
chromatin of schizophrenia subject affected 5/8 GpG nucleotides
(Fig. 2A lower panel) and was significant (Wilcoxon Signed Ranks
Test, p = 0.018). In contrast, the CpG methylation frequencies at
intron 2 were very similar in cases and controls (Fig. 2A, lower
panel, and Fig. 2C) and were approximately 25% in both cohorts;
these differences were not significant. Therefore, the deficit in
prefrontal GAD1 mRNA levels in this cohort of schizophrenia
subjects (Fig. 2, see also Methods) is associated with a selective
decrease in DNA methylation in repressive GAD1 chromatin at the
site of the proximal gene promoter.
Among various GAD1 single nucleotide polymorphisms (SNP’s),
two are positioned within 2kb of the transcription start site
(rs3749034 and rs2270335). These two SNP’s are included in
a GAD1 haplotype that confers genetic risk for childhood-onset
schizophrenia and accelerated loss of frontal gray matter [5]. In
order to rule out that GAD1 genotypes were different in the cases
and controls of the present study, we determined allele frequencies
Figure 2. GAD1 DNA methylation in prefrontal cortex of subjects with schizophrenia and comparison subjects. (A) (upper panel) GAD1 DNA
methylation profile in open (H4K4me3) and repressive (H3K27me3) chromatin. Percentage of methylated GAD1 CpG residues in DNA from
immunoprecipitates (y-axis, N , anti-H3K4me3;g , anti-H3K27me3) for 12 CpG’s (shown in red) positioned between bp-1150 to +3400 relative to GAD1
transcription start site. Primer pairs marked by arrows (N= 3–15 control subjects/CpG dinucleotide); (lower panel) averaged levels of methylation for
each of the 12 GAD1 CpG residues (see Fig. 2, upper panel) in schizophrenia subjects (S) , expressed relative to control, C (S/C, y-axis). Notice
decreased methylation of 5/8 CpG’s at the GAD1 promoter of schizophrenia subjects (B,C ) Averaged frequency of DNA methylation at across the 8
CpG’s at the GAD1 (B ) proximal promoter (see Fig. 2A, upper panel) and (C) intron no. 2 in schizophrenia and matched control subjects, as indicated
(N= 12 clones/primer pair/case or control). Data shown for open (‘‘K4’’ =H3Kme3) and repressive (‘‘K27’’ =H3K27me3) chromatin separately. Notice
significant deficit in repressive chromatin-associated DNA methylation at the GAD1 promoter in schizophrenia subjects.
doi:10.1371/journal.pone.0000809.g002
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for the two SNP’s. In both cohorts, allele frequencies were
identical, which is expected given their close proximity (,1.5 kb)
[Schizophrenia subjects, allele (1/1) 57%, (1/2) 29%, (2/2) 14%;
controls (1/1) 79%, (1/2) 14%, (2/2) 7%]. Notably, the case and
control cohort showed no significant difference in the number of
subjects bi-allelic for the common allele (1/1), which defines the at
risk haplotype [5] (Pearson chi-square X2=0.47, df = 1, p = 0.5).
Furthermore, overall allele frequencies were not significantly
different between the two cohorts (Fisher’s Exact Test).
DISCUSSION
To our knowledge, the present study is the first to assess DNA
methylation in human brain separately for open and repressive
chromatin. In the open chromatin fractions of the present study,
which were defined by trimethylation of a specific histone lysine
residue (H3K4) [14,15], GAD1 DNA methylation was overall
much lower, in comparison to repressive chromatin that is defined
by trimethylation of another lysine residue, H3K27 [15].
However, even in repressive/silenced chromatin, only a fraction
of GAD1 CpG dinucleotides (,30% for intron 2, and ,5% at the
promoter) are subjected to DNA methylation in human prefrontal
cortex.
Given that DNA methylation around the proximal promoter
typically contributes to transcriptional repression, it was expected
that subjects with schizophrenia show increased GAD1 DNA
methylation. Instead, we observed for the repressive chromatin
fraction of schizophrenia subjects a significant decrease in CpG
methylation at the proximal GAD1 promoter. Further studies are
necessary in order to determine if these changes are related to
altered GAD1 gene transcription. Notably, the schizophrenia
subjects of the present study had lower GAD1 mRNA levels in
comparison to the matched control (see Methods and Fig. 3). One
plausible explanation would be that in the affected cases, there is
an increased proportion of GAD1 nucleosomes tagged with the
repressive mark, H3K27me3, but without concomitant methyla-
tion of the genomic DNA (Fig. 4). Therefore, repressive
chromatin-associated histone methylation at the GAD1 locus in
schizophrenia appears to be, at least in part, independent from
CpG methylation. The present study faces an important limitation
because reliable PCR amplification across multiple subjects was
achieved only for a dozen GAD1 CpG’s, and we cannot exclude an
important role for any of the approximately 400 additional CpG
sites that surround the first 5 kb of GAD1 transcription start site.
Therefore, our findings have to be viewed as preliminary.
Furthermore, it will be of interest to find out in future studies
whether the observed DNA methylation deficits in H3K27me3-
tagged GAD1 nucleosomes of schizophrenia subjects are specific
for that gene, or part of a more widespread DNA methylation
defect of the disorder.
METHODS
All procedures were approved by the institutional review board of
the University of Massachusetts Medical School. Demographics,
postmortem confounds and RNA data for the case and control
cohorts are presented in Table 1. Each pair consisted of a subject
Figure 3. GAD1 mRNA levels in schizophrenia subjects and matched controls. Levels of GAD1 mRNA in 14 controls (C) matched to 14
schizophrenia (S) subjects, as determined by qRT-PCR separately for 3 different primer pairs spanning different exons. Data shown after log-
transformation and normalization with housekeeping gene transcript, b2-microglobulin.
doi:10.1371/journal.pone.0000809.g003
Figure 4. DNA methylation changes at GAD1 locus in schizophrenia.
(Top) schematic presentation of GAD1 CpG dinucleotides (open labels,
unmethylated and filled labels, methylated) in normal prefrontal cortex,
showing higher levels of DNA methylation in repressive
(‘‘K27’’ = H3K27me3) as opposed to open (‘‘K4’’ =H3K4me3) chromatin.
Notice overall low DNA methylation at proximal GAD1 promoter.
(Bottom) In schizophrenia, GAD1 promoter DNA methylation in
repressive chromatin (‘‘K27’’) is further decreased from control values.
A hypothetical but plausible mechanisms would be the conversion from
open chromatin to repressive chromatin that becomes tagged with the
histone mark, H3K27me3, but without additional DNA methylation.
doi:10.1371/journal.pone.0000809.g004
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with schizophrenia and a control matched for age, gender and
autolysis time. The prefrontal cortex of the 14 schizophrenia
subjects included in the present study showed, in comparison to
the matched control, a decrease in GAD1 mRNA levels, as
determined by qRT-PCR with 3 different sets of PCR primers and
normalization to the housekeeping gene transcript, b2-micro-
globulin (B2M) (Table 1 and Fig. 3). In addition, for 3 of the
matched pairs the decrease in GAD1 mRNA levels in the
schizophrenia subject had been observed in a previous study that
used in situ hybridization histochemistry [19]. The remaining 11
matched pairs were not included in that earlier study, but were
collected by the same brain bank and subjected to the same
diagnostic criteria and inclusion/exclusion criteria as previously
described [19].
For DNA methylation studies, nucleosomes first were extracted
from prefrontal cortex gray matter and then immunoprecipitated
with two anti-methyl-histone specific antibodies [anti-histone H3-
tri-methyl-lysine 4 (H3K4me3) and anti-H3-tri-methyl-lysine 27
(H3K27me3)] to separate open chromatin at sites of actual or
potential transcription from repressive and silenced chromatin,
exactly as described [17,18]. Salmon sperm as a blocking agent
was omitted and instead all samples were first pre-cleared by
30 min agarose pre-incubation prior to the immunoprecipitation
procedure. DNA purified from immunoprecipitates was subjected
to sodium bisulfite conversion followed by purification and elution,
using the EZ DNA methylation kit (Zymo research), according to
the manufacturer’s instructions. Methprimer software (http://
www.urogene.org/methprimer) was used to design primer pairs
for GAD1 sequences. Three primer pairs (Suppl. Table S1)
altogether covering 12 CpG’s positioned between 21120 to
+3400 bp from the GAD1 transcription start site, were choosen to
profile DNA methylation patterns in control brains (Fig. 2A upper
panel). PCR amplicons were gel-purified, subcloned into pCR4-
TOPO vector, purified in 96 well plates (Qiagen Turbo Miniprep)
and for each subject, 12 clones from each immunoprecipitate were
analyzed by sequencing. For each subject, DNA methylation levels
were expressed as % methylated CpG’s separately for each primer
pair, and differences between schizophrenia and control subjects
were evaluated by two sample t-test , or in case of non-normal
distribution, by Mann-Whitney test separately for open and
repressive chromatin fractions. Furthermore, for each case and
control, genotyping for selected GAD1 single nucleotide poly-
morphism was performed using matrix-assisted laser desorption/
inonization mass spectrometry (Sequenom), in conjunction with
SpecroDesign software for PCR and MassEXTEND primers.
Cell cultures
Neural stem cells were prepared from forebrain of E14.5 SASCO
SD rat embryos (Charles River). Live cells were plated out at 1.2–
1.46106 cells per 100-mm poly-l-lysine coated dishes pre-coated
with 15ug/ml poly-l-ornithine (sigma) and 1ug/ml fibonectin
(R&D systems), and treated daily with 10ug basic fibroblast growth
factor 2 (FGF2-R&D systems). At DIV5, cells were passaged and
plated out at 0.8–1.06106 cells per pre-coated plate and expanded
as above for a further 3–4 days (expansion approx 300%). Cells
were passaged again and plated out at 1.2–1.46106, and after 1–
2 days FGF2 was removed, cells washed once with media and then
resuspended in DMEM/M2/F12 media (Invitrogen) without
FGF2 but with 0.5 mM sodium valproate and with or without 1
micromol clozapine, and harvested after 4 days.
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0000809.s001 (0.03 MB
PDF)
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